Stockscreener 앱 받기
1.15
9.63%
0.101
시간 외 거래:
1.15
Revelation Biosciences Inc 주식(REVB)의 최신 뉴스
Armistice Capital (REVB) discloses 4.99% Revelation Biosciences stake via Master Fund - Stock Titan
Price to book forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
Price to sales forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
Revelation Biosciences, Inc. (REVBW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revelation Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Revelation Biosciences reports $3.3M net loss for Q2 2026, $11.5M cash on hand - TradingView
BRIEF-Revelation Biosciences Inc Q2 EPS USD -0.87 - TradingView
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 - Yahoo Finance
REVELATION BIOSCIENCES 2Q 2026: Net loss $(3.32M), EPS $(0.87) — 10-Q Summary - TradingView
Revelation Biosciences (Nasdaq: REVB) posts Q2 loss and flags cash risk - Stock Titan
REVB Q2'26 Earnings: EPS estimate is (0.83) USD - TradingView
REVB: Q2 net loss widened to $3.3M; Gemini targets a $94B market with cash runway through Q1 2027 - TradingView
Revelation aims to start kidney injury trial enrollment by year-end - Stock Titan
Revelation Biosciences Inc expected to post a loss of 83 cents a shareEarnings Preview - TradingView
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury - New Castle News
Revelation Biosciences (NASDAQ:REVB) secures FDA agreement setting single-study path for kidney drug Gemini - Kalkine
Revelation Biosciences Inc (REVB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Revelation Biosciences Inc (REVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc (REVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
REVB|Revelation Biosciences Inc|Price:1.050|Chg%:-0.010 - TradingKey
Revelation Biosciences Inc (REVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Revelation Biosciences Inc (REVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVB) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
REVB|Revelation Biosciences Inc|Price:1.060|Chg%:-0.030 - TradingKey
Revelation Biosciences Inc (REVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Inc. (REVB) Holds Steady at $1.15 as Consolidation ContinuesSentiment Shift - po-news-eg.net
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Daily Corinthian
Three New Hires Get Revelation Biosciences Stock Awards Through 2028 - Stock Titan
Revelation Biosciences Adopts Stockholder Rights Plan to Protect Investors and Maximize Value - Minichart
Revelation Biosciences Adopts Stockholder Rights Protection Plan - TipRanks
Why Is Revelation Biosciences (NASDAQ:REVB) in Focus Today? - Kalkine Media
Revelation Biosciences Announces Adoption of Stockholder Rights Plan - ACCESS Newswire
New plan lets Revelation investors buy discounted shares if a buyer crosses 10% - Stock Titan
Revelation Biosciences (REVB) Hovers Near Support Amid Modest DeclineBollinger Expansion - dars.gov.et
REVB Q1 2026 Earnings: EPS Misses Estimates Significantly Amid No Revenue; Stock Rises 3.85%Earnings Cycle Outlook - DonanımHaber
Revelation Biosciences, Inc. Warrant 2022-10.01.27 on Revelatn Biosci Financial Disclosures & SEC Filings - TradingView
Price to sales forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Price to earnings forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
Revelation Biosciences Inc. (REVB) Holds Steady Near Support as Micro-Cap Stock Shows Slight UptickATR Trailing Stop - dars.gov.et
REVB Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock Gains 6%Analyst Consensus Shift - dars.gov.et
Revelation Biosciences (REVB) Surges 6% as Biotech Stock Tests Key Resistance LevelJurik MA - dars.gov.et
Price to earnings forward of Revelation Biosciences, Inc. – BOATS:REVBW - TradingView
Revelation Biosciences, Inc. Actuals & Estimates (NASDAQ:REVB) - TradingView
ADTX Stock Price and Chart — OTC:ADTX - TradingView
Revelation Biosciences, Inc. Actuals & Estimates (BOATS:REVB) - TradingView
REVB Q1 2026 Earnings: EPS Miss Widens Loss, No Revenue Reported as Stock DeclinesLow Growth Earnings - dars.gov.et
REVB Forecast — Price Target — Prediction for 2027 - TradingView
Revelation Biosciences Inc (REVBW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Amends Executive Agreements and Bylaws, Announces CEO and CFO Changes – June 2026 - Minichart
Revelation Biosciences Updates Executive Contracts, Shareholder Actions - TipRanks
Revelation Biosciences updates employment agreements for CEO James Rolke and CFO Chester S. Zygmont, III - TradingView
Revelation Biosciences (NASDAQ: REVB) expands CEO/CFO protections and secures reverse split authority - Stock Titan
John Lowe, of Sayville, pleads guilty to insider trading scheme that netted $1 million in illegal profits - Newsday
Revelation Biosciences Inc (REVBW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Revelation Biosciences Inc (REVBW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVBW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
1.80%
1.77%
자본화:
|
볼륨(24시간):